Evaluation of the efficacy of the combination of osimertinib and brigatinib

Osimertinib and brigatinib, as two targeted drugs with significant efficacy in the treatment of lung cancer, have received widespread attention in recent years. When these two drugs are used together, their clinical efficacy is a matter of concern to many medical experts and patients. Osimertinib is a drug that can specifically block EGFR signaling in metastatic non-small cell lung cancer, thereby inhibiting the growth, proliferation and differentiation of cancer cells and inducing apoptosis. Brigatinib is a new type of dual inhibitor of ALK and EGFR. It has extensive preclinical activity against ALK resistance mutations and has become a research hotspot.

EGFR and ALK are two common driver gene mutations in non-small cell lung cancer. Some patients may develop resistance to a single drug during treatment, so it is particularly important to explore combination drug strategies. The combination of osimertinib and brigatinib aims to more comprehensively inhibit the growth of cancer cells through different mechanisms of action, improve the therapeutic effect, and may delay the development of drug resistance.

In multiple clinical trials, the combination of osimertinib and brigatinib has shown impressive efficacy. First of all, in terms of disease control, patients in the combined drug group had significantly longer progression-free survival (PFS) than those in the single drug group. This means that combined medication can more effectively control the progression of the disease and buy patients more time to survive.

Secondly, combination therapy also shows advantages in terms of objective response rate (ORR). Some patients experienced significant tumor shrinkage and even achieved partial or complete remission after using combination therapy. This effect was uncommon among single-drug groups.

For patients with brain metastases, combined medication also shows good therapeutic effects. Because brigatinib can cross the blood-brain barrier, combination therapy also has potential advantages in controlling brain metastases.

In terms of safety, no unexpected serious adverse reactions occurred in the combination group. Most patients were able to tolerate the combination treatment regimen, and only a few patients experienced mild to moderate adverse reactions such as diarrhea and nausea. These reactions were effectively controlled through appropriate medication adjustments and supportive treatment.

Although combination therapy shows significant efficacy in initial treatment, some patients may still develop drug resistance over time. In response to this problem, the medical community is actively exploring new treatment strategies, such as identifying resistance mechanisms through genetic testing and adjusting treatment plans accordingly. In addition, for patients who develop drug resistance after combined treatment, other treatments, such as immunotherapy or chemotherapy, can also be considered to further extend the patient's survival and improve their quality of life.

The combination of osimertinib and brigatinib has demonstrated significant clinical efficacy in the treatment of non-small cell lung cancer. Through different mechanisms of action, these two drugs can more effectively control the progression of the disease and improve patients' survival rate and quality of life. However, as treatment progresses, the issue of drug resistance still requires attention.

References:

https://www.nature.com/articles/ncomms14768